综述 |
|
|
|
|
组织因子与肿瘤患者静脉血栓栓塞 |
朱慧琦( ),应可净*( ) |
浙江大学医学院附属邵逸夫医院呼吸内科 国家呼吸疾病区域医疗中心, 浙江 杭州 310016 |
|
Tissue factors and venous thromboembolism in cancer patients |
ZHU Huiqi( ),YING Kejing*( ) |
Department of Respiratory Medicine, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, National Regional Medical Center for Respiratory Diseases, Hangzhou 310016, China |
1 |
PABINGER I , THALER J , AY C . Biomarkers for prediction of venous thromboembolism in cancer[J]. Blood, 2013, 122 (12): 2011- 2018
doi: 10.1182/blood-2013-04-460147
|
2 |
TIMP J F , BRAEKKAN S K , VERSTEEG H H et al. Epidemiology of cancer-associated venous thrombosis[J]. Blood, 2013, 122 (10): 1712- 1723
doi: 10.1182/blood-2013-04-460121
|
3 |
FALANGA A , PANOVA-NOEVA M , RUSSO L . Procoagulant mechanisms in tumour cells[J]. Best Pract Res Clin Haematol, 2009, 22 (1): 49- 60
doi: 10.1016/j.beha.2008.12.009
|
4 |
FALANGA A , MARCHETTI M , VIGNOLI A . Coagulation and cancer: biological and clinical aspects[J]. J Thromb Haemost, 2013, 11 (2): 223- 233
doi: 10.1111/jth.12075
|
5 |
EDWARDS R L , MORGAN D L , RICKLES F R . Animal tumor procoagulants: registry of the Subcommittee on Haemostasis and Malignancy of the Scientific and Standardization Committee, International Society of Thrombosis and Haemostasis[J]. Thromb Haemost, 1990, 63 (1): 133- 138
doi: 10.1055/s-0038-1645699
|
6 |
MACKMAN N , MORRISSEY J H , FOWLER B et al. Complete sequence of the human tissue factor gene, a highly regulated cellular receptor that initiates the coagulation protease cascade[J]. Biochemistry, 1989, 28 (4): 1755- 1762
doi: 10.1021/bi00430a050
|
7 |
ZAHRA S , ANDERSON J A , STIRLING D et al. Microparticles, malignancy and thrombosis[J]. Br J Haematol, 2011, 152 (6): 688- 700
doi: 10.1111/j.1365-2141.2010.08452.x
|
8 |
KOMIYAMA Y , PEDERSEN A H , KISIEL W . Proteolytic activation of human factors Ⅸ and Ⅹ by recombinant human factor Ⅶa: effects of calcium, phospholipids, and tissue factor[J]. Biochemistry, 1990, 29 (40): 9418- 9425
doi: 10.1021/bi00492a016
|
9 |
ZWICKER J I , LIEBMAN H A , NEUBERG D et al. Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy[J]. Clin Cancer Res, 2009, 15 (22): 6830- 6840
doi: 10.1158/1078-0432.CCR-09-0371
|
10 |
DRAKE T A , MORRISSEY J H , EDGINGTON T S . Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis[J]. AM J PATHOL, 1989, 134 (5): 1087- 1097
|
11 |
FLECK R A , RAO L V , RAPAPORT S I et al. Localization of human tissue factor antigen by immunostaining with monospecific, polyclonal anti-human tissue factor antibody[J]. Thromb Res, 1990, 59 (2): 421- 437
doi: 10.1016/0049-3848(90)90148-6
|
12 |
OTT I . Soluble tissue factor emerges from inflammation[J]. Circ Res, 2005, 96 (12): 1217- 1218
doi: 10.1161/01.RES.0000172745.09928.87
|
13 |
FONSECA R , CESARMAN-MAUS G , BRAGGIO E . Personalizing the use of circulating microparticle-associated tissue factor as a biomarker for recurrent thrombosis in patients with cancer[J]. J Clin Oncol, 2017, 35 (19): 2217- 2218
doi: 10.1200/JCO.2017.72.5341
|
14 |
MANLY D A , BOLES J , MACKMAN N . Role of tissue factor in venous thrombosis[J]. Annu Rev Physiol, 2011, 73:515- 525
doi: 10.1146/annurev-physiol-042210-121137
|
15 |
DVORAK H F , NAGY J A , DVORAK J T et al. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules[J]. Am J Pathol, 1988, 133 (1): 95- 109
|
16 |
AUWERDA J J , YUANA Y , OSANTO S et al. Microparticle-associated tissue factor activity and venous thrombosis in multiple myeloma[J]. Thromb Haemost, 2011, 105 (1): 14- 20
doi: 10.1160/TH10-03-0187
|
17 |
WANG J G , GEDDINGS J E , ALEMAN M M et al. Tumor-derived tissue factor activates coagulation and enhances thrombosis in a mouse xenograft model of human pancreatic cancer[J]. Blood, 2012, 119 (23): 5543- 5552
doi: 10.1182/blood-2012-01-402156
|
18 |
EDGINGTON T S , MACKMAN N , BRAND K et al. The structural biology of expression and function of tissue factor[J]. Thromb Haemost, 1991, 66 (1): 67- 79
doi: 10.1055/s-0038-1646375
|
19 |
PEPPELENBOSCH M P , VERSTEEG H H . Cell biology of tissue factor, an unusual member of the cytokine receptor family[J]. Trends Cardiovasc Med, 2001, 11 (8): 335- 339
doi: 10.1016/s1050-1738(01)00137-2
|
20 |
GORDON S G , MIELICKI W P . Cancer procoagulant: a factor X activator, tumor marker and growth factor from malignant tissue[J]. Blood Coagul Fibrinolysis, 1997, 8 (2): 73- 86
doi: 10.1097/00001721-199703000-00001
|
21 |
WOOD K E . Major pulmonary embolism: review of a pathophysiologic approach to the golden hour of hemodynamically significant pulmonary embolism[J]. Chest, 2002, 121 (3): 877- 905
doi: 10.1378/chest.121.3.877
|
22 |
BATTISTINI B . Modulation and roles of the endothelins in the pathophysiology of pulmonary embolism[J]. Can J Physiol Pharmacol, 2003, 81 (6): 555- 569
doi: 10.1139/y03-017
|
23 |
LAWSON C A , YAN S D , YAN S F et al. Monocytes and tissue factor promote thrombosis in a murine model of oxygen deprivation[J]. J Clin Invest, 1997, 99 (7): 1729- 1738
doi: 10.1172/JCI119337
|
24 |
WOEI-A-JIN F J , TESSELAAR M E , GARCIA RODRIGUEZ P et al. Tissue factor-bearing microparticles and CA19.9: two players in pancreatic cancer-associated thrombosis?[J]. Br J Cancer, 2016, 115 (3): 332- 338
doi: 10.1038/bjc.2016.170
|
25 |
AHAMED J , VERSTEEG H H , KERVER M et al. Disulfide isomerization switches tissue factor from coagulation to cell signaling[J]. Proc Natl Acad Sci U S A, 2006, 103 (38): 13932- 13937
doi: 10.1073/pnas.0606411103
|
26 |
PRANDONI P . Antithrombotic strategies in patients with cancer[J]. Thromb Haemost, 1997, 78 (1): 141- 144
doi: 10.1055/s-0038-1657517
|
27 |
ERNOFSSON M , THELIN S , SIEGBAHN A . Monocyte tissue factor expression, cell activation, and thrombin formation during cardiopulmonary bypass: a clinical study[J]. J Thoracic Cardiovas Surg, 1997, 113 (3): 576- 584
doi: 10.1016/S0022-5223(97)70373-8
|
28 |
CHUNG J , TABUCHI N , KOYAMA T . The increase in tissue factor-bearing leukocytes after off-pump coronary artery bypass surgery[J]. Thromb Haemost, 2008, 100 (5): 952- 954
doi: 10.1160/TH08-06-0349
|
29 |
DE MARTINO R R , GOODNEY P P , SPANGLER E L et al. Variation in thromboembolic complications among patients undergoing commonly performed cancer operations[J]. J Vasc Surg, 2012, 55 (4): 1035- 1040.e4
doi: 10.1016/j.jvs.2011.10.129
|
30 |
ALBRECHT S , MVLLER S , SIEGERT G et al. Plasma concentration of tissue factor and factor Ⅶ in patients after abdominal surgery[J]. Thromb Res, 1995, 77 (6): 557- 562
doi: 10.1016/0049-3848(95)00030-5
|
31 |
MERKOW R P , BILIMORIA K Y , MCCARTER M D et al. Post-discharge venous thromboembolism after cancer surgery: extending the case for extended prophylaxis[J]. Ann Surg, 2011, 254 (1): 131- 137
doi: 10.1097/SLA.0b013e31821b98da
|
32 |
HEIT J A , SILVERSTEIN M D , MOHR D N et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study[J]. Arch Intern Med, 2000, 160 (6): 809- 815
doi: 10.1001/archinte.160.6.809
|
33 |
GRACE R F , DAHLBERG S E , NEUBERG D et al. The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols[J]. Br J Haematol, 2011, 152 (4): 452- 459
doi: 10.1111/j.1365-2141.2010.08524.x
|
34 |
AMIR E , SERUGA B , NIRAULA S et al. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis[J]. J Natl Cancer Inst, 2011, 103 (17): 1299- 1309
doi: 10.1093/jnci/djr242
|
35 |
OPPELT P , BETBADAL A , NAYAK L . Approach to chemotherapy-associated thrombosis[J]. Vasc Med, 2015, 20 (2): 153- 161
doi: 10.1177/1358863X14568705
|
36 |
SENG S , LIU Z , CHIU S K et al. Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis[J]. J Clin Oncol, 2012, 30 (35): 4416- 4426
doi: 10.1200/JCO.2012.42.4358
|
37 |
FALANGA A , MARCHETTI M . Anticancer treatment and thrombosis[J]. Thromb Res, 2012, 129 (3): 353- 359
doi: 10.1016/j.thromres.2011.10.025
|
38 |
BACH R R , MOLDOW C F . Mechanism of tissue factor activation on HL-60 cells[J]. Blood, 1997, 89 (9): 3270- 3276
doi: 10.1182/blood.V89.9.3270
|
39 |
LYSOV Z , SWYSTUN L L , KURUVILLA S et al. Lung cancer chemotherapy agents increase procoagulant activity via protein disulfide isomerase-dependent tissue factor decryption[J]. Blood Coagul Fibrinolysis, 2015, 26 (1): 36- 45
doi: 10.1097/MBC.0000000000000145
|
40 |
JACOBSEN C , OECHSLE K , HAUSCHILD J et al. Regulation of tissue factor in NT2 germ cell tumor cells by cisplatin chemotherapy[J]. Thromb Res, 2015, 136 (3): 673- 681
doi: 10.1016/j.thromres.2015.07.002
|
41 |
BILLROTH T . General surgical pathology and therapy. Guidance for students and physicians. Lecture[J]. Khirurgiia (Mosk), 1991, (10): 136- 143
|
42 |
ELIZONDO P , FOGELSON A L . A mathematical model of venous thrombosis initiation[J]. Biophys J, 2016, 111 (12): 2722- 2734
doi: 10.1016/j.bpj.2016.10.030
|
43 |
FAILLE D , BOURRIENNE M C , DE RAUCOURT E et al. Biomarkers for the risk of thrombosis in pancreatic adenocarcinoma are related to cancer process[J]. Oncotarget, 2018, 9 (41): 26453- 26465
doi: 10.18632/oncotarget.25458
|
44 |
RONDON A , KROONE C , KAPTEIJN M Y et al. Role of tissue factor in tumor progression and cancer-associated thrombosis[J]. Semin Thromb Hemost, 2019, 45 (4): 396- 412
doi: 10.1055/s-0039-1687895
|
45 |
TSENG J C , CHANG L C , JIANG B Y et al. Elevated circulating levels of tissue factor-positive microvesicles are associated with distant metastasis in lung cancer[J]. J Cancer Res Clin Oncol, 2014, 140 (1): 61- 67
doi: 10.1007/s00432-013-1544-8
|
46 |
KHORANA A A , FRANCIS C W , MENZIES K E et al. Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer[J]. J Thromb Haemost, 2008, 6 (11): 1983- 1985
doi: 10.1111/j.1538-7836.2008.03156.x
|
47 |
TESSELAAR M E , ROMIJN F P , VAN DER LINDEN I K et al. Microparticle-associated tissue factor activity in cancer patients with and without thrombosis[J]. J Thromb Haemost, 2009, 7 (8): 1421- 1423
doi: 10.1111/j.1538-7836.2009.03504.x
|
48 |
KHORANA A A , AHRENDT S A , RYAN C K et al. Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer[J]. Clin Cancer Res, 2007, 13 (10): 2870- 2875
doi: 10.1158/1078-0432.CCR-06-2351
|
49 |
HRON G , KOLLARS M , WEBER H et al. Tissue factor-positive microparticles: cellular origin and association with coagulation activation in patients with colorectal cancer[J]. Thromb Haemost, 2007, 97 (1): 119- 123
doi: 10.1160/TH06-03-0141
|
50 |
AY C , VORMITTAG R , DUNKLER D et al. D-dimer and prothrombin fragment 1+2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study[J]. J Clin Oncol, 2009, 27 (25): 4124- 4129
doi: 10.1200/JCO.2008.21.7752
|
51 |
UNO K , HOMMA S , SATOH T et al. Tissue factor expression as a possible determinant of thromboembolism in ovarian cancer[J]. Br J Cancer, 2007, 96 (2): 290- 295
doi: 10.1038/sj.bjc.6603552
|
52 |
GEZELIUS E , FLOU KRISTENSEN A , BENDAHL P O et al. Coagulation biomarkers and prediction of venous thromboembolism and survival in small cell lung cancer: a sub-study of RASTEN - a randomized trial with low molecular weight heparin[J]. PLoS One, 2018, 13 (11): e0207387
doi: 10.1371/journal.pone.0207387
|
53 |
ZUCCHELLA M , PACCHIARINI L , TACCONI F et al. Different expression of procoagulant activity in human cancer-cells cultured "in vitro" or in cells isolated from human tumor-tissues[J]. Thromb Haemost, 1993, 69 (4): 335- 338
doi: 10.1055/s-0038-1651608
|
54 |
HAMADA K , KURATSU J , SAITOH Y et al. Expression of tissue factor correlates with grade of malignancy in human glioma[J]. Cancer, 1996, 77 (9): 1877- 1883
doi: 10.1002/(SICI)1097-0142(19960501)77:9<1877::AID-CNCR18>3.0.CO;2-X
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|